{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:00:15Z","timestamp":1750636815302,"version":"3.37.3"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T00:00:00Z","timestamp":1727222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T00:00:00Z","timestamp":1727222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s40744-024-00711-z","type":"journal-article","created":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T06:05:29Z","timestamp":1727244329000},"page":"1649-1664","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and Safety of Tofacitinib in Patients with Psoriatic Arthritis or Ankylosing Spondylitis by Cigarette Smoking Status"],"prefix":"10.1007","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4639-0775","authenticated-orcid":false,"given":"Alexis","family":"Ogdie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0686-7102","authenticated-orcid":false,"given":"Lars E.","family":"Kristensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3143-1084","authenticated-orcid":false,"given":"Enrique R.","family":"Soriano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3734-1242","authenticated-orcid":false,"given":"Servet","family":"Akar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanhui","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3516-5289","authenticated-orcid":false,"given":"David","family":"Gruben","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7113-1014","authenticated-orcid":false,"given":"Lara","family":"Fallon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2712-1668","authenticated-orcid":false,"given":"Cassandra D.","family":"Kinch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9074-0592","authenticated-orcid":false,"given":"Dafna D.","family":"Gladman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,25]]},"reference":[{"key":"711_CR1","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1056\/NEJMra1505557","volume":"376","author":"CT Ritchlin","year":"2017","unstructured":"Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376:957\u201370.","journal-title":"N Engl J Med"},{"key":"711_CR2","doi-asserted-by":"crossref","unstructured":"Sieper J, Braun J, Rudwaleit M, Boonen A, Zink A. Ankylosing spondylitis: an overview. Ann Rheum Dis. 2002;61(Suppl 3):iii8\u201318.","DOI":"10.1136\/ard.61.suppl_3.iii8"},{"key":"711_CR3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1136\/annrheumdis-2016-209775","volume":"76","author":"R Agca","year":"2017","unstructured":"Agca R, Heslinga SC, Rollefstad S, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015\/2016 update. Ann Rheum Dis. 2017;76:17\u201328.","journal-title":"Ann Rheum Dis"},{"key":"711_CR4","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-002170","volume":"8","author":"M Wieczorek","year":"2022","unstructured":"Wieczorek M, Gwinnutt JM, Ransay-Colle M, et al. Smoking, alcohol consumption and disease-specific outcomes in rheumatic and musculoskeletal diseases (RMDs): systematic reviews informing the 2021 EULAR recommendations for lifestyle improvements in people with RMDs. RMD Open. 2022;8: e002170.","journal-title":"RMD Open"},{"key":"711_CR5","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1136\/annrheumdis-2014-205389","volume":"74","author":"P H\u00f8jgaard","year":"2015","unstructured":"H\u00f8jgaard P, Glintborg B, Hetland ML, et al. Association between tobacco smoking and response to tumour necrosis factor alpha inhibitor treatment in psoriatic arthritis: results from the DANBIO registry. Ann Rheum Dis. 2015;74:2130\u20136.","journal-title":"Ann Rheum Dis"},{"key":"711_CR6","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1093\/rheumatology\/kev392","volume":"55","author":"B Glintborg","year":"2016","unstructured":"Glintborg B, H\u00f8jgaard P, Lund Hetland M, et al. Impact of tobacco smoking on response to tumour necrosis factor-alpha inhibitor treatment in patients with ankylosing spondylitis: results from the Danish nationwide DANBIO registry. Rheumatology (Oxford). 2016;55:659\u201368.","journal-title":"Rheumatology (Oxford)"},{"key":"711_CR7","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","volume":"377","author":"D Gladman","year":"2017","unstructured":"Gladman D, Rigby W, Azevedo VF, et al. Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N Engl J Med. 2017;377:1525\u201336.","journal-title":"N Engl J Med"},{"key":"711_CR8","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","volume":"377","author":"P Mease","year":"2017","unstructured":"Mease P, Hall S, FitzGerald O, et al. Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J Med. 2017;377:1537\u201350.","journal-title":"N Engl J Med"},{"key":"711_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002559","volume":"9","author":"X Leng","year":"2023","unstructured":"Leng X, Lin W, Liu S, et al. Efficacy and safety of tofacitinib in Chinese patients with active psoriatic arthritis: a phase 3, randomised, double-blind, placebo-controlled study. RMD Open. 2023;9: e002559.","journal-title":"RMD Open"},{"key":"711_CR10","doi-asserted-by":"publisher","first-page":"E270","DOI":"10.1016\/S2665-9913(21)00010-2","volume":"3","author":"P Nash","year":"2021","unstructured":"Nash P, Coates LC, Fleishaker D, et al. Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study. Lancet Rheumatol. 2021;3:E270\u201383.","journal-title":"Lancet Rheumatol"},{"key":"711_CR11","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1136\/annrheumdis-2016-210322","volume":"76","author":"D van der Heijde","year":"2017","unstructured":"van der Heijde D, Deodhar A, Wei JC, et al. Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study. Ann Rheum Dis. 2017;76:1340\u20137.","journal-title":"Ann Rheum Dis"},{"key":"711_CR12","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1136\/annrheumdis-2020-219601","volume":"80","author":"A Deodhar","year":"2021","unstructured":"Deodhar A, Sliwinska-Stanczyk P, Xu H, et al. Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2021;80:1004\u201313.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 10","key":"711_CR13","first-page":"S995","volume":"64","author":"JM Kremer","year":"2013","unstructured":"Kremer JM, Greenberg JD, Turesson C, et al. Effects of smoking history on response to treatment with tofacitinib in patients with rheumatoid arthritis [abstract]. Arthritis Rheum. 2013;64(Suppl 10):S995.","journal-title":"Arthritis Rheum"},{"key":"711_CR14","doi-asserted-by":"crossref","unstructured":"Rubin DT, Torres J, Regueiro M, et al. Association between smoking status and the efficacy and safety of tofacitinib in patients with ulcerative colitis. Crohns Colitis 360. 2024;6:otae004.","DOI":"10.1093\/crocol\/otae004"},{"key":"711_CR15","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.3899\/jrheum.140172","volume":"41","author":"PS Helliwell","year":"2014","unstructured":"Helliwell PS, FitzGerald O, Fransen J. Composite disease activity and responder indices for psoriatic arthritis: a report from the GRAPPA 2013 meeting on development of cutoffs for both disease activity states and response. J Rheumatol. 2014;41:1212\u20137.","journal-title":"J Rheumatol"},{"key":"711_CR16","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/1477-7525-1-79","volume":"1","author":"K Webster","year":"2003","unstructured":"Webster K, Cella D, Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: properties, applications, and interpretation. Health Qual Life Outcomes. 2003;1:79.","journal-title":"Health Qual Life Outcomes"},{"key":"711_CR17","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1136\/ard.2010.138594","volume":"70","author":"P Machado","year":"2011","unstructured":"Machado P, Landew\u00e9 R, Lie E, et al. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis. 2011;70:47\u201353.","journal-title":"Ann Rheum Dis"},{"key":"711_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0123579","volume":"10","author":"S Dare","year":"2015","unstructured":"Dare S, Mackay DF, Pell JP. Relationship between smoking and obesity: a cross-sectional study of 499,504 middle-aged adults in the UK general population. PLoS ONE. 2015;10: e0123579.","journal-title":"PLoS ONE"},{"key":"711_CR19","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1093\/rheumatology\/keaa093","volume":"59","author":"SS Zhao","year":"2020","unstructured":"Zhao SS, Goodson NJ, Robertson S, Gaffney K. Smoking in spondyloarthritis: unravelling the complexities. Rheumatology (Oxford). 2020;59:1472\u201381.","journal-title":"Rheumatology (Oxford)"},{"key":"711_CR20","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.3390\/ijerph15051033","volume":"15","author":"A Strzelak","year":"2018","unstructured":"Strzelak A, Ratajczak A, Adamiec A, Feleszko W. Tobacco smoke induces and alters immune responses in the lung triggering inflammation, allergy, asthma and other lung diseases: a mechanistic review. Int J Environ Res Public Health. 2018;15:1033.","journal-title":"Int J Environ Res Public Health"},{"key":"711_CR21","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1080\/1744666X.2022.2064275","volume":"18","author":"AI Venetsanopoulou","year":"2022","unstructured":"Venetsanopoulou AI, Voulgari PV, Drosos AA. Janus kinase versus TNF inhibitors: where we stand today in rheumatoid arthritis. Expert Rev Clin Immunol. 2022;18:485\u201393.","journal-title":"Expert Rev Clin Immunol"},{"key":"711_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-001595","volume":"7","author":"GR Burmester","year":"2021","unstructured":"Burmester GR, Nash P, Sands BE, et al. Adverse events of special interest in clinical trials of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and psoriasis with 37 066 patient-years of tofacitinib exposure. RMD Open. 2021;7: e001595.","journal-title":"RMD Open"},{"key":"711_CR23","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.semarthrit.2014.10.007","volume":"44","author":"S Mathieu","year":"2015","unstructured":"Mathieu S, Pereira B, Soubrier M. Cardiovascular events in ankylosing spondylitis: an updated meta-analysis. Semin Arthritis Rheum. 2015;44:551\u20135.","journal-title":"Semin Arthritis Rheum"},{"issue":"Suppl 3","key":"711_CR24","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/jdv.12163","volume":"27","author":"C Horreau","year":"2013","unstructured":"Horreau C, Pouplard C, Brenaut E, et al. Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review. J Eur Acad Dermatol Venereol. 2013;27(Suppl 3):12\u201329.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"711_CR25","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1136\/annrheumdis-2014-205675","volume":"74","author":"A Ogdie","year":"2015","unstructured":"Ogdie A, Yu Y, Haynes K, et al. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis. 2015;74:326\u201332.","journal-title":"Ann Rheum Dis"},{"key":"711_CR26","doi-asserted-by":"publisher","first-page":"473","DOI":"10.2174\/1570161117666190426164306","volume":"18","author":"C Papagoras","year":"2020","unstructured":"Papagoras C, Voulgari PV, Drosos AA. Cardiovascular disease in spondyloarthritides. Curr Vasc Pharmacol. 2020;18:473\u201387.","journal-title":"Curr Vasc Pharmacol"},{"key":"711_CR27","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.2147\/TCRM.S138000","volume":"14","author":"F Pouresmaeili","year":"2018","unstructured":"Pouresmaeili F, Kamalidehghan B, Kamarehei M, Goh YM. A comprehensive overview on osteoporosis and its risk factors. Ther Clin Risk Manag. 2018;14:2029\u201349.","journal-title":"Ther Clin Risk Manag"},{"key":"711_CR28","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1080\/1744666X.2019.1543591","volume":"15","author":"E Pezzolo","year":"2019","unstructured":"Pezzolo E, Naldi L. The relationship between smoking, psoriasis and psoriatic arthritis. Expert Rev Clin Immunol. 2019;15:41\u20138.","journal-title":"Expert Rev Clin Immunol"},{"key":"711_CR29","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1093\/rheumatology\/key371","volume":"58","author":"S Zhao","year":"2019","unstructured":"Zhao S, Jones GT, Macfarlane GJ, et al. Associations between smoking and extra-axial manifestations and disease severity in axial spondyloarthritis: results from the BSR Biologics Register for Ankylosing Spondylitis (BSRBR-AS). Rheumatology (Oxford). 2019;58:811\u20139.","journal-title":"Rheumatology (Oxford)"},{"key":"711_CR30","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1136\/ard-2022-223715","volume":"82","author":"LE Kristensen","year":"2023","unstructured":"Kristensen LE, Danese S, Yndestad A, et al. Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance. Ann Rheum Dis. 2023;82:901\u201310.","journal-title":"Ann Rheum Dis"},{"key":"711_CR31","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3389\/fmed.2018.00062","volume":"5","author":"A Molt\u00f3","year":"2018","unstructured":"Molt\u00f3 A, Nikiphorou E. Comorbidities in spondyloarthritis. Front Med (Lausanne). 2018;5:62.","journal-title":"Front Med (Lausanne)"},{"key":"711_CR32","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/art.40726","volume":"71","author":"JA Singh","year":"2019","unstructured":"Singh JA, Guyatt G, Ogdie A, et al. Special article: 2018 American College of Rheumatology\/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis. Arthritis Rhematol. 2019;71:5\u201332.","journal-title":"Arthritis Rhematol"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-024-00711-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-024-00711-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-024-00711-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T15:12:48Z","timestamp":1731424368000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-024-00711-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,25]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["711"],"URL":"https:\/\/doi.org\/10.1007\/s40744-024-00711-z","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"type":"print","value":"2198-6576"},{"type":"electronic","value":"2198-6584"}],"subject":[],"published":{"date-parts":[[2024,9,25]]},"assertion":[{"value":"16 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Alexis Ogdie is a consultant for AbbVie, Amgen, Bristol Myers Squibb, Celgene, CorEvitas, Eli Lilly, Gilead Sciences, GSK, Janssen, Novartis, Pfizer Inc, and UCB, and has received grant\/research support from AbbVie, Amgen, Novartis, and Pfizer Inc. Lars E. Kristensen is a consultant for AbbVie, Biogen, Eli Lilly, Galapagos NV, Gilead Sciences, Janssen, Pfizer\u00a0Inc, Sanofi, and UCB, and has received grant\/research support from AbbVie, Eli Lilly, Pfizer Inc, and UCB. Enrique R. Soriano is an advisor for Janssen, a consultant for AbbVie, Eli Lilly, Janssen, Novartis, Pfizer\u00a0Inc, and UCB, and has received grant\/research support from AbbVie, Janssen, Novartis, Pfizer Inc, Roche, and UCB. Servet Akar is an advisor for AbbVie, Amgen, Eli Lilly, Novartis, Pfizer\u00a0Inc, Sanofi, TRPharm, and UCB. Yanhui Sun was an employee and shareholder of Pfizer Inc at the time of the study, and is currently an employee of Rundo Med-Tech, Shanghai, China. David\u00a0Gruben and Lara Fallon are employees and shareholders of Pfizer Inc. Cassandra D. Kinch was an employee and shareholder of Pfizer Inc at the time of the study. Dafna D. Gladman is a consultant for AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Galapagos, Gilead Sciences, Janssen, Novartis, Pfizer Inc, and UCB, and has received grant\/research support from AbbVie, Amgen, Celgene, Eli Lilly, Novartis, Pfizer Inc, and UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All studies were conducted in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice Guidelines of the International Council for Harmonisation and were approved by the relevant Institutional Review Board and\/or Independent Ethics Committee at each investigational site [\u2013]. Patients provided written, informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}